Atara Biotherapeutics Inc (NAS:ATRA)
$ 10.28 -1.35 (-11.61%) Market Cap: 58.33 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Atara Biotherapeutics Inc and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel Corporate Call Transcript

Oct 04, 2021 / 12:30PM GMT
Release Date Price: $436.25 (-0.29%)
Operator

Good morning, everyone. Thank you for standing by, and welcome to the Atara Biotherapeutics Conference Call. (Operator Instructions) Please be advised that today's call is being recorded.

I'd now like to hand the call over to Eric Hyllengren, Vice President of Investor Relations and Finance at Atara Biotherapeutics. Please go ahead, sir.

Eric Hyllengren
Atara Biotherapeutics, Inc. - VP of IR & Finance

Thank you, operator. Good morning, everyone. and welcome to Atara's Strategic Collaboration Conference Call. On today's call, members from the Atara executive team will discuss our recently announced strategic collaboration with Pierre Fabre. Earlier today, we issued a joint press release announcing that Atara and Pierre Fabre have entered into a strategic collaboration to commercialize tab-cel. This press release and a summary slide about the collaboration are available in the Investors and Media section at atarabio.com.

Joining me on today's call are: Dr. Pascal Touchon, President and Chief Executive Officer; Utpal Koppikar, Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot